Company Overview
We are a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. Our internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Our lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that we are developing as an oral, once-daily treatment for Type 2 diabetes. Our first Phase 3 clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c as monotherapy for the treatment of Type 2 diabetes. We commenced our Phase 3 clinical program in the third quarter of 2008. Our second product candidate is a protease inhibitor currently in pre-clinical development for the treatment of hepatitis C virus, or HCV, infection.
We intend to maximize the value of our product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building our own sales and marketing force.